GSK announced today that it has completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of patients with respiratory and inflammatory diseases.

The acquisition of Aiolos includes AIO-001, a potentially best-in-class long-acting anti-lymphopoietin stromayetic antibody (TSLP) ready to enter Phase II clinical development for the treatment of adult asthma patients.

AIO-001 could expand GSK's portfolio of respiratory biologics to potentially reach the 40% of severe asthma patients with low T2 inflammation (a type of overactive immune response associated with asthma).

Tony Wood, GSK's Chief Scientific Officer, said: 'Given the limited treatment options for asthma patients with low T2 inflammation, we look forward to using our deep respiratory expertise to potentially bring a long-acting biologic to a larger proportion of the 315 million asthma patients. '

Copyright (c) 2024 All rights reserved.